Interleukin Genetics Files Form 10-K/A For Fiscal Year 2004
06/30/2005
INTERLEUKIN GENETICS FILES FORM 10-K/A FOR FISCAL YEAR 2004
WALTHAM, MA – JUNE 30, 2005 – Interleukin Genetics, Inc. (OTCBB: ILGNE) today announced that it has filed a Form 10-K/A amending Item 8 and Item 9A of its Annual Report on Form 10-K for the year ended December 31, 2004. Item 9A in the Form 10-K/A includes management’s completed assessment of the Company’s internal controls over financial reporting as of December 31, 2004 as required pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (“SOX 404”). Item 8 includes an opinion from Grant Thornton with respect to the Company’s financial statements and an attestation to management’s SOX 404 assessment as of December 31, 2004.
Also today, prior to filing the 10-K/A, the company received notification from the NASD rescheduling the hearing of its appeal of its potential delisting until July 14, 2005. The Company believes that the filing of this Form 10-K/A will fully satisfy the SEC and NASD requirements under SOX 404.
About Interleukin
Interleukin Genetics is a biotechnology company focused on developing personalized health products. The company uses functional genomics to help in the development of risk assessment tests, pharmacogenetic tests, nutritional and therapeutic products based on the genetic variations in people. Interleukin's current programs focus on cardiovascular disease, osteoporosis, periodontal disease and weight management. Interleukin expects that these programs will lead to products that will personalize the selection of nutritional and therapeutic products and enable consumers to manage their health care. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com.
Certain statements contained herein are “forward-looking” statements including statements regarding filing a 2004 Form 10-K/A and delisting of the company’s common stock. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the results of our hearing before the NASD and those risks and uncertainties described in our annual report on Form 10-K, our quarterly reports on Form 10-Q and in other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.
For Interleukin Genetics:
Fenel M. Eloi (781) 398-0700